On Tuesday, Novo Nordisk sued Eli Lilly for allegedly misleading the public in direct-to-consumer ads that compare Eli Lilly’s GLP-1s Mounjaro and Zepbound to Novo Nordisk-made Ozempic and Wegovy.
“The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk’s medicines,” states the lawsuit, which Novo Nordisk filed in the federal district court in New Jersey.
Eli Lilly rejected this claim in an email Tuesday to The News & Observer, arguing the companies’ respective treatments for weight loss were compared in a randomized clinical trial. “Novo is asking a court to stop Lilly from communicating the results of that trial,” Eli Lilly wrote. “We stand firmly behind our advertising.”…